- Tilray Brands reported first-quarter net revenue of $257.1 million, a 23% increase year-over-year, but missed the consensus estimate of $266.9 million.
- The beverages segment outperformed slightly, with revenue of $101.5 million compared to the estimate of $101 million.
- Cannabis revenue decreased by 13% year-over-year to $56.1 million, falling short of the expected $70.2 million.
- Wellness revenue remained relatively flat, increasing by only 0.2% year-over-year to $15.3 million, missing the estimate of $16.9 million.
- Distribution revenue saw a 14% increase year-over-year, reaching $84.3 million, which exceeded the estimate of $81 million.
- Adjusted EBITDA was $9.21 million, down 9.6% year-over-year and below the estimate of $10.7 million.
- Tilray reported a loss per share of 32 cents, compared to a break-even point last year.
- Tilray is recognised as a leading cannabis producer with over 6 million square feet of cultivation capacity across Canada, Portugal, and Germany, positioned in major legally regulated markets with a significant EU-GMP certified footprint.
- Analyst ratings for Tilray include 3 buys, 6 holds, and 1 sell.
“`
Tilray Inc on Smartkarma
Analyst coverage of Tilray Inc on Smartkarma reveals insightful information from Ξ±SK Primers. In their report titled “Primer: Tilray Inc (TLRY US) – Aug 2026,” it is highlighted that Tilray Brands has transformed into a global consumer packaged goods company, expanding beyond its core cannabis offerings. The company’s operations now encompass beverage alcohol, wellness products, and pharmaceutical distribution, diversifying its revenue streams and reducing exposure to the volatile Canadian cannabis market. Key growth drivers include the international medical cannabis segment, particularly in Europe, and the distribution business through CC Pharma, with significant year-over-year revenue growth in the international cannabis market. Despite this positive outlook, Tilray’s history of unprofitability and cash burn, along with shareholder dilution from acquisitions, are factors to consider.
A look at Tilray Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 5 | |
| Dividend | 1 | |
| Growth | 2 | |
| Resilience | 2 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 2.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Investment analysts are closely monitoring the long-term outlook for Tilray Inc, a pharmaceutical company known for developing cannabis-based medicines, drugs, drops, and oil products. Looking at the Smartkarma Smart Scores, Tilray Inc is rated highly in terms of value, scoring a 5 out of 5 which indicates a strong valuation perspective. This suggests that the company is regarded favorably in terms of its intrinsic value and potential for growth.
However, when it comes to factors like dividends, growth, resilience, and momentum, Tilray Inc has received lower scores ranging from 1 to 2. This indicates that the company may not be as strong in these areas compared to its valuation. Despite this, analysts are optimistic about Tilray Inc‘s potential due to its solid value score and position as a pharmaceutical company offering unique cannabis-based products to a global client base.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars
